Buy FOXO4-DRI Europe
Buy FOXO4-DRI Europe. Senolytic D-retro-inverso peptide for cellular senescence research. ≥99% purity. Fast EU delivery.
What is FOXO4-DRI?
FOXO4-DRI is a D-retro-inverso peptide designed to selectively induce apoptosis in senescent cells by disrupting the FOXO4-p53 protein interaction. Developed based on research by Peter de Keizer and colleagues at Erasmus University Medical Centre, FOXO4-DRI represents a targeted approach to senolytic therapy. For published research, see PubMed studies on FOXO4-DRI{:target=“_blank” rel=“noopener”}.
In senescent cells, FOXO4 sequesters p53 in the nucleus, preventing apoptosis and maintaining senescent cell viability. FOXO4-DRI disrupts this interaction, releasing p53 to trigger selective apoptosis of senescent cells.
Best-Peptides supplies research-grade FOXO4-DRI with guaranteed ≥99% purity and full analytical documentation.
How Does FOXO4-DRI Work?
FOXO4-p53 Disruption
- Competitive binding - Displaces endogenous FOXO4 from p53
- p53 liberation - Releases p53 from nuclear sequestration
- Apoptosis induction - p53-mediated cell death in senescent cells
- Senescent selectivity - Minimal effect on healthy cells
D-Retro-Inverso Design
- D-amino acids - Protease-resistant configuration
- Reversed sequence - Preserved side-chain topology
- Cell penetration - Enhanced membrane permeability
- Extended stability - Resistance to enzymatic degradation
Senescence Clearance
- SA-β-gal reduction - Decreased senescence-associated markers
- SASP attenuation - Reduced senescence-associated secretory phenotype
- Tissue rejuvenation - Improved tissue function post-clearance
- Selective action - Sparing of non-senescent cells
Research Applications
Cellular Senescence
- Senolytic efficacy - Senescent cell clearance quantification
- p53-FOXO4 interaction - Protein-protein interaction studies
- Senescence markers - SA-β-gal, p16, p21 expression analysis
Ageing Research
- Age-related pathology - Disease model intervention studies
- Tissue rejuvenation - Functional improvement assessment
- Healthspan extension - Preclinical longevity studies
Comparative Studies
- Senolytic comparison - FOXO4-DRI vs dasatinib/quercetin
- Selectivity profiling - Cell-type specific effects
- DRI peptide design - D-retro-inverso methodology validation
FOXO4-DRI Specifications
| Specification | Detail |
|---|---|
| CAS Number | Not assigned |
| Molecular Formula | D-retro-inverso peptide |
| Molecular Weight | ~5000 Da |
| Composition | All-D amino acid retro-inverso construct |
| Purity | ≥99% (HPLC) |
| Appearance | White lyophilised powder |
Storage and Handling
| Condition | Temperature | Duration |
|---|---|---|
| Lyophilised | -20°C | Up to 24 months |
| Reconstituted | 2-8°C | Up to 4 weeks |
Ordering Information
| Size | Price |
|---|---|
| 10 × 10 mg | €650 |
Minimum order: €200 | Minimum €100 per order line
Why Choose Best-Peptides for FOXO4-DRI?
- Guaranteed ≥99% purity - HPLC verified
- Full documentation - COA with every order
- EU laboratory tested - Quality assured
- Fast delivery - Express shipping available across Europe
- Research support - Technical assistance
Research Use Statement
For laboratory research only. Not intended for human or veterinary use. Researchers should follow all applicable regulations.
Specifications
| CAS No. | |
|---|---|
| Molecular Weight | ~5000 Da |
| Purity | ≥ 99% |
| Storage | -20°C recommended (research-only) |
| Available Sizes | 10 × 10 mg vials |
| Price Range | €650 per pack |
FAQ
FOXO4-DRI is a D-retro-inverso peptide designed to disrupt the FOXO4-p53 interaction in senescent cells. It is studied as a senolytic agent that selectively induces apoptosis in senescent cells while sparing healthy cells, with applications in ageing and age-related disease research.
In senescent cells, FOXO4 binds and sequesters p53, preventing p53-mediated apoptosis. FOXO4-DRI competes with endogenous FOXO4 for p53 binding, disrupting this interaction and releasing p53 to trigger apoptosis selectively in senescent cells.
A D-retro-inverso (DRI) peptide uses D-amino acids in reversed sequence to mimic the side-chain topology of the native L-peptide while conferring resistance to proteolytic degradation. This gives FOXO4-DRI enhanced stability and cell penetration compared to the L-form.
Store lyophilised FOXO4-DRI at -20°C for long-term stability. Once reconstituted, keep at 2-8°C and use within 4 weeks. The D-amino acid composition provides excellent stability against enzymatic degradation.
Our FOXO4-DRI is ≥99% pure as verified by HPLC. Each batch includes a Certificate of Analysis with purity data, D-amino acid confirmation, and mass spectrometry identity verification.
Yes, FOXO4-DRI is commonly studied alongside dasatinib, quercetin, navitoclax, and other senolytic compounds to compare selectivity, mechanism, and efficacy in clearing senescent cells from different tissue types.
Reconstitute in sterile DMSO or bacteriostatic water. For DMSO reconstitution, add solvent slowly and vortex gently. For aqueous solutions, add water along the vial wall and swirl. Aliquot to avoid freeze-thaw cycles.
FOXO4-DRI is available in 10 mg vials, supplied in packs of 10 × 10 mg for research applications.
Customer Reviews (12)
Based on 12 reviews
Dr. Stefan Krämer • 2025-01-25Verified Purchase
Our senescence clearing studies require ultra-pure FOXO4-DRI. Best-Peptides delivers consistently. SA-β-gal reduction data aligns with the de Keizer paper perfectly.
Groningen Ageing Biology Lab • 2025-01-18Verified Purchase
FOXO4-DRI quality is superb. Selective senescent cell apoptosis clearly demonstrated in our fibroblast models.
Dr. Nathalie Garnier • 2025-01-11Verified Purchase
Fast delivery to France, outstanding quality. Our p53 nuclear translocation studies are producing clear results with this batch.
Berlin Senescence Research Institute • 2025-01-04Verified Purchase
Consistent quality for our senolytic research programme. Best-Peptides is our preferred European source for FOXO4-DRI.
Dr. Cristina Torres • 2024-12-28Verified Purchase
Independent analysis confirms ≥99% purity and D-amino acid configuration. Essential for our ageing intervention studies.
Stockholm Gerontology Centre • 2024-12-21Verified Purchase
FOXO4-DRI shows remarkable selectivity in our mixed cell population assays. Quality and documentation are outstanding.
Dr. Francesco Moretti • 2024-12-14Verified Purchase
Arrived within 3 days. Product quality is excellent for our cellular senescence programme.
Vienna Anti-Ageing Lab • 2024-12-07Verified Purchase
Excellent FOXO4-DRI. p53-FOXO4 disruption clearly observable in our immunoprecipitation assays.
Dr. Hanna Virtanen • 2024-11-30Verified Purchase
Perfect for senescence clearance studies. The DRI modification provides excellent experimental stability.
Lisbon Biogerontology Lab • 2024-11-23Verified Purchase
Multiple orders, always consistent. Critical for our age-related disease research.
Dr. Willem Bakker • 2024-11-16Verified Purchase
Easy ordering, rapid delivery to Netherlands. FOXO4-DRI quality is exceptional.
Zurich Longevity Research Lab • 2024-11-09Verified Purchase
High-quality FOXO4-DRI with comprehensive documentation. Highly recommended for European senescence researchers.
Related Products
View Complete Catalog
